Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIAT
Ratios

Ultragenyx Pharmaceutical (RARE) Leases (2019 - 2023)

Historic Leases for Ultragenyx Pharmaceutical (RARE) over the last 5 years, with Q3 2023 value amounting to $26.4 million.

  • Ultragenyx Pharmaceutical's Leases fell 808.32% to $26.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was $26.4 million, marking a year-over-year decrease of 808.32%. This contributed to the annual value of $26.0 million for FY2022, which is 2568.98% down from last year.
  • According to the latest figures from Q3 2023, Ultragenyx Pharmaceutical's Leases is $26.4 million, which was down 808.32% from $19.2 million recorded in Q2 2023.
  • Ultragenyx Pharmaceutical's Leases' 5-year high stood at $40.5 million during Q4 2020, with a 5-year trough of $19.2 million in Q2 2023.
  • Its 5-year average for Leases is $31.9 million, with a median of $32.7 million in 2022.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Leases soared by 5560.72% in 2020 and then plummeted by 3847.98% in 2023.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Leases stood at $30.3 million in 2019, then surged by 33.62% to $40.5 million in 2020, then decreased by 13.79% to $34.9 million in 2021, then decreased by 25.69% to $26.0 million in 2022, then grew by 1.8% to $26.4 million in 2023.
  • Its Leases was $26.4 million in Q3 2023, compared to $19.2 million in Q2 2023 and $22.9 million in Q1 2023.